Literature DB >> 31822818

Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome.

David W Greening1,2, Michael Notaras3, Maoshan Chen4, Rong Xu2, Joel D Smith5, Lesley Cheng2, Richard J Simpson2, Andrew F Hill2, Maarten van den Buuse6,7,8.   

Abstract

Methamphetamine (Meth) abuse has reached epidemic proportions in many countries and can induce psychotic episodes mimicking the clinical profile of schizophrenia. Brain-derived neurotrophic factor (BDNF) is implicated in both Meth effects and schizophrenia. We therefore studied the long-term effects of chronic Meth exposure in transgenic mice engineered to harbor the human BDNFVal66Met polymorphism expressed via endogenous mouse promoters. These mice were chronically treated with an escalating Meth regime during late adolescence. At least 4 weeks later, all hBDNFVal66Met Meth-treated mice exhibited sensitization confirming persistent behavioral effects of Meth. We used high-resolution quantitative mass spectrometry-based proteomics to biochemically map the long-term effects of Meth within the brain, resulting in the unbiased detection of 4808 proteins across the mesocorticolimbic circuitry. Meth differentially altered dopamine signaling markers (e.g., Dat, Comt, and Th) between hBDNFVal/Val and hBDNFMet/Met mice, implicating involvement of BDNF in Meth-induced reprogramming of the mesolimbic proteome. Targeted analysis of 336 schizophrenia-risk genes, as well as 82 growth factor cascade markers, similarly revealed that hBDNFVal66Met genotype gated the recruitment of these factors by Meth in a region-specific manner. Cumulatively, these data represent the first comprehensive analysis of the long-term effects of chronic Meth exposure within the mesocorticolimbic circuitry. In addition, these data reveal that long-term Meth-induced brain changes are strongly dependent upon BDNF genetic variation, illustrating how drug-induced psychosis may be modulated at the molecular level by a single genetic locus.
© 2019. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31822818     DOI: 10.1038/s41380-019-0617-8

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  69 in total

1.  The prevalence of psychotic symptoms among methamphetamine users.

Authors:  Rebecca McKetin; Jennifer McLaren; Dan I Lubman; Leanne Hides
Journal:  Addiction       Date:  2006-10       Impact factor: 6.526

2.  A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis.

Authors:  M Sato
Journal:  Ann N Y Acad Sci       Date:  1992-06-28       Impact factor: 5.691

3.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.

Authors:  Andreas Meyer-Lindenberg; Robert S Miletich; Philip D Kohn; Giuseppe Esposito; Richard E Carson; Mario Quarantelli; Daniel R Weinberger; Karen Faith Berman
Journal:  Nat Neurosci       Date:  2002-03       Impact factor: 24.884

4.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.

Authors:  J M Wilson; K S Kalasinsky; A I Levey; C Bergeron; G Reiber; R M Anthony; G A Schmunk; K Shannak; J W Haycock; S J Kish
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

Review 5.  Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.

Authors:  Linda Chang; Daniel Alicata; Thomas Ernst; Nora Volkow
Journal:  Addiction       Date:  2007-04       Impact factor: 6.526

6.  Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report.

Authors:  A Iwanami; A Sugiyama; N Kuroki; S Toda; N Kato; Y Nakatani; N Horita; T Kaneko
Journal:  Acta Psychiatr Scand       Date:  1994-06       Impact factor: 6.392

7.  Long-lasting decrease in dopamine uptake sites following repeated administration of methamphetamine in the rat striatum.

Authors:  M Nakayama; T Koyama; I Yamashita
Journal:  Brain Res       Date:  1993-01-22       Impact factor: 3.252

8.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

Authors:  A Abi-Dargham; R Gil; J Krystal; R M Baldwin; J P Seibyl; M Bowers; C H van Dyck; D S Charney; R B Innis; M Laruelle
Journal:  Am J Psychiatry       Date:  1998-06       Impact factor: 18.112

9.  Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine.

Authors:  G C Wagner; G A Ricaurte; L S Seiden; C R Schuster; R J Miller; J Westley
Journal:  Brain Res       Date:  1980-01-06       Impact factor: 3.252

Review 10.  Methamphetamine-associated psychosis.

Authors:  Kathleen M Grant; Tricia D LeVan; Sandra M Wells; Ming Li; Scott F Stoltenberg; Howard E Gendelman; Gustavo Carlo; Rick A Bevins
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

View more
  9 in total

1.  Causal influences of neuroticism on mental health and cardiovascular disease.

Authors:  Fuquan Zhang; Ancha Baranova; Chao Zhou; Hongbao Cao; Jiu Chen; Xiangrong Zhang; Mingqing Xu
Journal:  Hum Genet       Date:  2021-05-11       Impact factor: 4.132

2.  Medial prefrontal cortex Notch1 signalling mediates methamphetamine-induced psychosis via Hes1-dependent suppression of GABAB1 receptor expression.

Authors:  Tong Ni; Li Zhu; Shuai Wang; Weili Zhu; Yanxue Xue; Yingjie Zhu; Dongliang Ma; Hongyan Wang; Fanglin Guan; Teng Chen
Journal:  Mol Psychiatry       Date:  2022-06-22       Impact factor: 15.992

Review 3.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

4.  Gene-based association analysis identifies 190 genes affecting neuroticism.

Authors:  Nadezhda M Belonogova; Irina V Zorkoltseva; Yakov A Tsepilov; Tatiana I Axenovich
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

5.  Association of PICK1 and BDNF variations with increased risk of methamphetamine dependence among Iranian population: a case-control study.

Authors:  Mahla Asghari; Soheila Abedini; Sohrab Saghafi Khadem; Amir Tajbakhsh; Maliheh Alimardani; Abolfazl Nesaei Bajestani; Forough Alipoor; Maryam Alidoust; Amir Savardashtaki; Peyman Hashemian; Alireza Pasdar
Journal:  BMC Med Genomics       Date:  2021-01-26       Impact factor: 3.063

6.  Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis.

Authors:  Li He; Yanhui Liao; Qiuxia Wu; Tieqiao Liu
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

7.  Brain-Derived Neurotrophic Factor Val66Met polymorphism interacts with adolescent stress to alter hippocampal interneuron density and dendritic morphology in mice.

Authors:  Rachel Anne Hill; Adrienne Mary Grech; Michael J Notaras; Mauricio Sepulveda; Maarten van den Buuse
Journal:  Neurobiol Stress       Date:  2020-09-28

8.  Proteomic dissection of large extracellular vesicle surfaceome unravels interactive surface platform.

Authors:  Alin Rai; Haoyun Fang; Bethany Claridge; Richard J Simpson; David W Greening
Journal:  J Extracell Vesicles       Date:  2021-11

9.  Impairments in the Default Mode and Executive Networks in Methamphetamine Users During Short-Term Abstinence.

Authors:  Mingqiang Gong; Yunxia Shen; Wenbin Liang; Zhen Zhang; Chunxue He; Mingwu Lou; ZiYu Xu
Journal:  Int J Gen Med       Date:  2022-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.